- Home
- KC vs RNA Comparison
KC vs RNA Comparison
Compare KC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KC
- RNA
- Stock Information
- Founded
- KC 2012
- RNA 2012
- Country
- KC China
- RNA United States
- Employees
- KC N/A
- RNA N/A
- Industry
- KC Computer Software: Prepackaged Software
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- KC Technology
- RNA Health Care
- Exchange
- KC Nasdaq
- RNA Nasdaq
- Market Cap
- KC 4.3B
- RNA 4.0B
- IPO Year
- KC 2020
- RNA 2020
- Fundamental
- Price
- KC $12.60
- RNA $69.85
- Analyst Decision
- KC Strong Buy
- RNA Buy
- Analyst Count
- KC 4
- RNA 20
- Target Price
- KC $13.55
- RNA $69.26
- AVG Volume (30 Days)
- KC 1.6M
- RNA 8.4M
- Earning Date
- KC 11-18-2025
- RNA 11-07-2025
- Dividend Yield
- KC N/A
- RNA N/A
- EPS Growth
- KC N/A
- RNA N/A
- EPS
- KC N/A
- RNA N/A
- Revenue
- KC $1,177,715,737.00
- RNA $10,729,000.00
- Revenue This Year
- KC $25.35
- RNA N/A
- Revenue Next Year
- KC $16.46
- RNA $108.26
- P/E Ratio
- KC N/A
- RNA N/A
- Revenue Growth
- KC 20.27
- RNA 1.23
- 52 Week Low
- KC $2.70
- RNA $21.51
- 52 Week High
- KC $22.26
- RNA $70.51
- Technical
- Relative Strength Index (RSI)
- KC 41.12
- RNA 79.61
- Support Level
- KC $12.53
- RNA $69.50
- Resistance Level
- KC $13.93
- RNA $72.05
- Average True Range (ATR)
- KC 0.43
- RNA 1.86
- MACD
- KC 0.02
- RNA 2.28
- Stochastic Oscillator
- KC 30.37
- RNA 91.52
About KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.